Home Healthcare Pharmaceuticals Anti-VEGF Market

Anti-VEGF Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration), By Drug (Small Molecules, Biologics), By Type (VEGF-A Inhibitors, VEGF-B Inhibitors, VEGF-C Inhibitors, Placenta Growth Factor Inhibitors), By Distribution Channel (Hospitals, Specialty Clinics, Mail Order Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR1632DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti-VEGF Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Eylea
    2. Lucentis
    3. Beovu
  2. Anti-VEGF Market, By Disease 2022-2034 (USD MILLION/ Units)
    1. Macular Edema
    2. Diabetic Retinopathy
    3. Retinal Vein Occlusion
    4. Age-Related Macular Degeneration
  3. Anti-VEGF Market, By Drug 2022-2034 (USD MILLION/ Units)
    1. Small Molecules
      1. Pazopanib
      2. Sunitinib
      3. Sorafenib
      4. Regorafenib
      5. Cabozantinib
      6. Lenvatinib
      7. Ponatinib
      8. Axitinib
      9. Tivozanib
      10. Vandetanib
      11. Anlotinib
      12. Apatinib
      13. Fruquintinib
      14. Surufatinib
    2. Biologics
      1. Bevacizumab
      2. Aflibercept
      3. Ramucirumab
  4. Anti-VEGF Market, By Type 2022-2034 (USD MILLION/ Units)
    1. VEGF-A Inhibitors
    2. VEGF-B Inhibitors
    3. VEGF-C Inhibitors
    4. Placenta Growth Factor Inhibitors
  5. Anti-VEGF Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Specialty Clinics
    3. Mail Order Pharmacies
  6. Regional Anti-VEGF Market
    1. North America
      1. North America Anti-VEGF Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
      2. North America Anti-VEGF Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-Related Macular Degeneration
      3. North America Anti-VEGF Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        2. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
      4. North America Anti-VEGF Market By Type 2022-2034 (USD MILLION/ Units)
        1. VEGF-A Inhibitors
        2. VEGF-B Inhibitors
        3. VEGF-C Inhibitors
        4. Placenta Growth Factor Inhibitors
      5. North America Anti-VEGF Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Mail Order Pharmacies
      6. U.S.
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      7. Canada
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
    2. Europe
      1. Europe Anti-VEGF Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
      2. Europe Anti-VEGF Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-Related Macular Degeneration
      3. Europe Anti-VEGF Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        2. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
      4. Europe Anti-VEGF Market By Type 2022-2034 (USD MILLION/ Units)
        1. VEGF-A Inhibitors
        2. VEGF-B Inhibitors
        3. VEGF-C Inhibitors
        4. Placenta Growth Factor Inhibitors
      5. Europe Anti-VEGF Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Mail Order Pharmacies
      6. U.K.
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      7. Germany
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      8. France
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      9. Spain
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      10. Italy
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      11. Russia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      12. Nordic
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      13. Benelux
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      14. Rest of Europe
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
    3. APAC
      1. APAC Anti-VEGF Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
      2. APAC Anti-VEGF Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-Related Macular Degeneration
      3. APAC Anti-VEGF Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        2. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
      4. APAC Anti-VEGF Market By Type 2022-2034 (USD MILLION/ Units)
        1. VEGF-A Inhibitors
        2. VEGF-B Inhibitors
        3. VEGF-C Inhibitors
        4. Placenta Growth Factor Inhibitors
      5. APAC Anti-VEGF Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Mail Order Pharmacies
      6. China
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      7. Korea
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      8. Japan
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      9. India
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      10. Australia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      11. Taiwan
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      12. South East Asia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      13. Rest of Asia-Pacific
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
    4. Middle East and Africa
      1. Middle East and Africa Anti-VEGF Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
      2. Middle East and Africa Anti-VEGF Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-Related Macular Degeneration
      3. Middle East and Africa Anti-VEGF Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        2. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
      4. Middle East and Africa Anti-VEGF Market By Type 2022-2034 (USD MILLION/ Units)
        1. VEGF-A Inhibitors
        2. VEGF-B Inhibitors
        3. VEGF-C Inhibitors
        4. Placenta Growth Factor Inhibitors
      5. Middle East and Africa Anti-VEGF Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Mail Order Pharmacies
      6. UAE
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      7. Turkey
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      8. Saudi Arabia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      9. South Africa
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      10. Egypt
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      11. Nigeria
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      12. Rest of MEA
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
    5. LATAM
      1. LATAM Anti-VEGF Market By Product 2022-2034 (USD MILLION/ Units)
        1. Eylea
        2. Lucentis
        3. Beovu
      2. LATAM Anti-VEGF Market By Disease 2022-2034 (USD MILLION/ Units)
        1. Macular Edema
        2. Diabetic Retinopathy
        3. Retinal Vein Occlusion
        4. Age-Related Macular Degeneration
      3. LATAM Anti-VEGF Market By Drug 2022-2034 (USD MILLION/ Units)
        1. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        2. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
      4. LATAM Anti-VEGF Market By Type 2022-2034 (USD MILLION/ Units)
        1. VEGF-A Inhibitors
        2. VEGF-B Inhibitors
        3. VEGF-C Inhibitors
        4. Placenta Growth Factor Inhibitors
      5. LATAM Anti-VEGF Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Mail Order Pharmacies
      6. Brazil
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      7. Mexico
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      8. Argentina
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      9. Chile
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      10. Colombia
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
      11. Rest of LATAM
        1. Eylea
        2. Lucentis
        3. Beovu
        4. Macular Edema
        5. Diabetic Retinopathy
        6. Retinal Vein Occlusion
        7. Age-Related Macular Degeneration
        8. Small Molecules
          1. Pazopanib
          2. Sunitinib
          3. Sorafenib
          4. Regorafenib
          5. Cabozantinib
          6. Lenvatinib
          7. Ponatinib
          8. Axitinib
          9. Tivozanib
          10. Vandetanib
          11. Anlotinib
          12. Apatinib
          13. Fruquintinib
          14. Surufatinib
        9. Biologics
          1. Bevacizumab
          2. Aflibercept
          3. Ramucirumab
        10. VEGF-A Inhibitors
        11. VEGF-B Inhibitors
        12. VEGF-C Inhibitors
        13. Placenta Growth Factor Inhibitors
        14. Hospitals
        15. Specialty Clinics
        16. Mail Order Pharmacies
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.